Industry leading Fluorescence, Bioluminescence and X-Ray Imaging - All-In-One benchtop instrument! The IVIS® Lumina XRMS (x-ray multi-species optical imaging system) adds to the versatility of the IVIS Lumina XR by offering the flexibility to image large animals up to 500 grams with precise optical and X-Ray overlay.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
For research use only. Not for use in diagnostic procedures.
The Lumina XRMS includes state of the art spectral unmixing for sensitive multispectral imaging to monitor multiple biological events in the same animal. Use our Living Image® software to automate all the controls and settings required for seamless image acquisition and processing. Typical X-ray image acquisitions take only 10 seconds and can be overlaid with both optical and photographic images.
Superior Optical Imaging with Spectral Unmixing
The IVIS Lumina XRMS Series III is capable of imaging all common fluorescent and bioluminescent reporters or dyes. The system is equipped with up to 21 filter sets to image reporters that emit from green to near-infrared. High resolution, sharp cut-off filters are simply interchangeable to achieve the highest performance, sensitivity and spectral unmixing. The Lumina XRMS imaging system also accommodates Petri dishes or micro-titer plates for in vitro imaging.
The system can incorporate premium animal handling features such as a heated stage, gas anesthesia connections and a syringe injection system for simultaneous compound administration. Living Image software yields high-quality, reproducible, quantitative results incorporating instrument calibration, background subtraction and the image algorithms. Simple user guided spectral unmixing allows detection and separation of multiple reporters, and Living Image provides the precise overlay to see your optical reporters together with anatomical surface or X-ray features.
Features and Benefits:
For additional publications, please visit Google Scholar.
|Imaging Modality||Optical Imaging|
|Optical Imaging Classification||Bioluminescence imaging, Fluorescence Imaging|
|Product Brand Name||IVIS|
Cerenkov Emission from radioisotopes in tissue,Optical imaging detects photons in the visible range of the electromagnetic,spectrum. PET and SPECT imaging instruments are sensitive to photons in the much,higher energy range of x-rays and gamma rays. While the PET and SPECT probes,which can generate Cerenkov light in tissue will continue to produce the relevant,gamma- and x-rays, visible photons will be produced from the Cerenkov emission,which the IVIS® will detect.,In beta decay emitters such as PET probes and isotopes such as 90Y, 177Lu, 131I and 32P,the beta particle will travel in the tissue until it either annihilates with an electron or,loses momentum due to viscous electromagnetic forces.,It is possible that the beta (electron or positron),is relativistic, traveling faster than the speed,of light in the tissue. While it is impossible,to travel than the speed of light in a vacuum,(c), the speed of light in tissue is v = c / n,where n is the tissue index of refraction and,n = 1. Cerenkov photons will be generated,by a relativistic charged particle in a dielectric medium such as tissue.
Aside from the traditional small-molecule chemotherapeutics or targeted therapy agents that have been widely used in the clinic for decades, a new type of cancer therapeutics based on oncolytic viruses has recently gained attention in the field of research. Oncolytic viruses are genetically modified viruses capable of delivering therapeutic gene payload to cancer cells.
There are many types of oncolytic viruses each having a different tumor-targeting mechanism. This application note highlights using Sindbis pseudovirus genetically modified with firefly luciferase reporter gene to non-invasively evaluate, monitor, and quantify oncolytic viral infection in living tumors and subsequent virus-host interactions in real-time using IVIS® optical imaging.
With the potential to treat a wide range of disease, from organ damage to congenital defects, stem cell research and tissue engineering form the underlying basis of regenerative medicine. Significant advances in the science of skin regeneration, for example, have now made it possible to develop and grow artificial skin grafts in a lab for treatment of burn victims. Other therapeutic applications include the use of stem cells to treat and repair central nervous system diseases such as ischemia and cerebral palsy, cardiovascular diseases, as well as autoimmune diseases including type I diabetes.
CAR T therapy has achieved tremendous success in treating blood malignancies, however treating solid tumors with CAR T cells has proven to be challenging due to several factors such as on-tumor, off-tumor toxicity.
Read this case study where researchers from University of Pennsylvania created a mouse model that expresses tumor associated antigens in normal tissue to study off-tumor CART-T cell toxicity. These studies used optical imaging on the IVIS® platform to longitudinally monitor off-tumor antigen expression, tumor progression, and CAR-T cell trafficking in live animals.
Obesity is a global epidemic that is the fifth leading cause of death worldwide and in the US alone, nearly 85% of adults are expected to be overweight or obese by 2030. In addition to the increased risk of overall mortality, obesity is associated with an increased risk for other metabolic disorders such as diabetes and heart disease which pose a significant burden to health care systems.
Read this case study to learn how researchers at the Joslin Diabetes Center in Boston, Massachusetts used the IVIS® optical imaging system to visualize and quantify CRISPR/Cas9 engineered adipose tissue in a mouse model to study the prevention of obesity and obesity-related metabolic disorders.
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Influenza is a highly infectious airborne disease with an important societal burden. Annual epidemics have occurred throughout history causing tens of millions of deaths. Even a run-of-the-mill influenza infection can be debilitating to otherwise healthy people, and lethal to those who are elderly or frail, so vaccinations are important. Because of seasonal antigenic drift and antiviral resistance of the virus there is a critical need for the development of new and novel vaccines and antiviral drugs. In vivo optical imaging has emerged as a powerful, non-invasive tool to track viral load and therapeutic efficacy of vaccines and immunotherapies in small animal models.
Read how researchers at the NIH, NIAID, Emory University, and University of Wisconsin used the IVIS® optical imaging platform to successfully quantify and track viral load in mice and demonstrated that vaccine of human mAb administration has a protective or therapeutic effect in mice challenged with the influenza virus.
A large percentage of Type 2 diabetes mortality is related to cardiovascular complications. Consequently, there is a critical need for creating novel therapeutics that not only manage blood glucose levels, but also reduce the risk of developing cardiovascular diseases.
Liraglutide (Lira) is a recently approved drug used to treat Type II diabetes with excellent hypoglycemic effects while also improving cardiovascular function in patients. However its short half-life requires daily injections increasing the risk of poor patient compliance and other complications.
Read this publication review to learn how researchers used a Type II diabetes mouse model and optical imaging with the IVIS® platform to evaluate a nanoparticle system that offers a sustained and controlled release of Lira that overcomes the challenges of the short half-life of the drug.
IVIS Lumina XR Series III Integrating Gold Standard Bioluminescence, Fluorescence and X-Ray In Vivo Technologies. The IVIS Lumina XR Series III from PerkinElmer provides an expandable, sensitive imaging system that is easy to use for fluorescent, bioluminescent, radioistopic and X-Ray imaging in vivo. As the leading optical imaging platform for in vivo analysis, IVIS systems include a range of practical accessories developed through experience in research laboratories worldwide.
Adaptive Fluorescence Background Subtraction Pre-clinical in vivo imaging technical note for IVIS Imaging Systems. Instrument background occurs when excitation light leaks through the emission filter. This occurs more frequently when the excitation and emission filters are narrowly separated. The ring you see is a result of non specific light reflecting off of the stage at an incident angle and passing through the filter causing what appears as leakage around the edges.
Auto-exposure technical note for IVIS pre-clinical imaging systems
Subtracting Background ROI from a Sequence
Determine Saturation for IVIS imaging systems - technical note
Technical notes for Drawing ROIs for IVIS in vivo imaging systems. The circle, square, free draw, or grid (for well plates) can be used to draw your ROIs. ROI selections,are user-specific and are dependent on the model being analyzed. It is irrelevant which shape that is used for a particular ROI.
Acquisition of High Resolution Images. This quick reference guide is for those researchers who wish to perform analysis that requires high resolution including in vitro studies when one may want to discern aspects about cell layers, ex vivo tissue imaging, or imaging of tissue slices. You will not need this resolution in most in vivo studies.
Not only is it possible to load multiple images as a group, for example multiple days of a longitudinal study, but it is also possible to load multiple images and Overlay them i.e. bioluminescent tumor with fluorescent targeted drug acquired in two separate images.
For many studies, it may be desirable to open a group of images together, for example, analyzing multiple days of longitudinal study side by side using the same scale.
Subject ROI using IVIS imaging systems
Working with Image Math. Image Math is a rudimentary but effective method for Spectrum and Lumina users to subtract background from images without performing Spectral Unmixing.
Viral diseases have emerged and re-emerged throughout history, and as the human population continues to increase globally, so will the frequency of viral pandemics. Not only have Ebola and COVID-19 demonstrated most recently mankind’s vulnerability to contagious diseases, but also the challenges we are faced with from a therapeutic standpoint.Read how non-invasive optical imaging enables the most intricate host-pathogen interactions to be visualized and monitored in disease models that mimic what is seen in humans. Not only does optical imaging play an important role in better understanding the complex mechanisms of viral biology, it plays a vital role in the discovery and development of new drug and vaccine candidates.
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.